FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION or representative shall have entered into a non-disclosure agreement in respect of such Confidential Information in favour of the Discloser on terms requiring at least [**] years of confidentiality from the date of disclosure of such Confidential Information but that are in all other respects materially similar to the provisions of this clause 12. For greater certainty, BIS’ representatives shall include the DLA Contract Authority, the DLA Project Manager and all representatives of members of [**].
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ATTACHMENT 3 PROBLEM REPORT Each problem report will contain all information necessary to reproduce or demonstrate the occurrence of the problem. Problem reports will be in English and will be delivered electronically in a format to be provided by Digimarc. Problem reports will contain: · Date problem was encountered · Detailed description of the problem, including the frequency with which the problem occurs · Name and version number of the program / system component that exhibits the problem · Step by step instructions to reproduce the problem · All data files required to reproduce the problem · [**]Manufacturer and Model · CPU type and speed · Amount of memory · Operating System and Version · Disk Configuration (number of drives, total space per drive, free space per drive) · Display Adapter Model, Resolution, Number of colors · Peripheral configuration (where applicable)[**]XXXXX driver and version number · [**] · Severity of problem · Contact information for person to contact for further information (name, phone number, FAX number, email address) Licensee agrees to work with Digimarc to provide reasonable additional information and perform reasonable additional tests, as requested by Digimarc, to assist Digimarc in resolution of the problem.
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. To the extent possible, DMD will seek insurance coverage and will tender any defense to an insurer affording coverage.
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS 11 presentations. Each party shall be responsible for its respective sales expenses. Any sales prospect for which ROCKWELL requested joint sales effort shall not be solicited by VOICETEK alone, unless mutually agreed to in writing.
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. All other provisions of the Agreement shall remain unaltered and be given full force and effect. Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Agreement.
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. so excluded, without invalidating the remaining provisions of this Agreement; and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. All other provisions of the Agreement remain unchanged and in full force and effect. TUFTS UNIVERSITY PARATEK PHARMACEUTICALS, INC. By: /s/ Xxxxxx X. Xxxxx By: /s/ Xxxxxx X. Xxxxxxx (signature) (signature) Xxxxxx X. Xxxxx Xxxxxx X. Xxxxxxx Name Name Senior Director, University Development Executive Vice President Title Title 12/23/97 12/29/97 Date Date THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. TUFTS UNIVERSITY -- PARATEK PHARMACEUTICALS, INC. AMENDMENT NO. 2 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 Exhibit A is hereby amended to include: • Patent application entitled: "[***]" Continuation in Part of U.S. patent No.: [***], Filed [***], Notice of Allowance [***]. • Provisional patent application entitled: "[***]", Serial No.: [***], Filed [***] • Patent application jointly owned with [***], entitled: "[***]", Serial No.: [***], Filed [***] • Provisional patent application entitled: "[***]", Serial No.: [***], Filed [***] • Patent application entitled: "[***]", Serial No.: [***], Filed [***] • Patent application entitled: "[***]", U.S. patent No. [***], Issued [***], Divisional Application of U.S. patent No. [***] All other provisions of the Agreement remain unchanged and in full force and effect. TUFTS UNIVERSITY PARATEK PHARMACEUTICALS, INC. By: /s/ Xxxxxxxx Xxxxxx By: /s/ Xxxxxx X. Xxxxxxx (signature) (signature) Xxxxxxxx Xxxxxx Xxxxxx X. Xxxxxxx Name Name Executive Vice President and Associate Xxxxxxx for Research Chief Operating Officer Title Title 7/31/98 7/31/98 Date Date THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC AMENDMENT NO. 3 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 Exhibit A and all amendments and modifications are deleted and replaced in their entirety by the attached Exhibit X. Xxxxx’ ownership interests in all patents, patent applications and disclosures listed in the attached Exhibit A are hereby incorporated into the License Agreement dated February 1, 1997. All other provisions of the Agreement as amended remain in full force and effect.
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT) days after any breakage or defect in an Item becomes apparent, whether or not said breakage or defect can reasonably be expected to occur in any other Aircraft, and the Buyer shall inform the Seller in sufficient detail about the breakage or defect to enable the Seller to determine whether said breakage or defect is subject to this Service Life Policy.
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. STRATEGIC SUPPLY AGREEMENT This Strategic Supply Agreement (this “Agreement”), dated as of June 26, 2018 (the “Effective Date”), is by and between Pall Corporation, a New York corporation having its principal place of business at 00 Xxxxxx Xxxx Xxxxx, Xxxx Xxxxxxxxxx, Xxx Xxxx 00000 (“Pall”) and Kindred Biosciences, Inc., a Delaware corporation having its principal place of business at 0000 Xxxxxxxx Xxx. #000, Xxxxxxxxxx XX 00000 (“KindredBio”). Pall and Kindred Bio are collectively referred to herein as the “Parties” and individually as a “Party”.
